Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation

Cell Death and Disease

Volumn 7, Issue 2, 2016, Pages

  Blondel, S ^a   Egesipe, A L ^a   Picardi, P ^b   Jaskowiak, A L ^a   Notarnicola, M ^c   Ragot, J ^a   Tournois, J ^a   Le Corf, A ^a   Brinon, B ^a   Poydenot, P ^a,i   Georges, P ^a   Navarro, C ^d,e   Pitrez, P R ^f   Ferreira, L ^f   Bollot, G ^g   Bauvais, C ^g   Laustriat, D ^a   Mejat, A ^h   De Sandre Giovannoli, A ^d,e   Levy, N ^d,e   Bifulco, M ^b   Peschanski, M ^a   Nissan, X ^a   more..

^a I Stem   (France)

^b UNIVERSITY OF SALERNO   (Italy)

^c NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^d AIX MARSEILLE UNIVERSITY   (France)

^e INSERM   (France)

^f UNIVERSITY OF COIMBRA   (Portugal)

^g Synsight   (France)

^h UNIVERSITÉ DE LYON   (France)

ⁱ CYTOO SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2-AMINOPYRIMIDINE; FARNESYL TRANS TRANSFERASE; GERANYLTRANSFERASE; LAMIN A; MOLECULAR LIBRARY; PRELAMIN A; PYRIMIDINE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; BINDING SITE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MOLECULAR DOCKING; MOLECULAR LIBRARY; PATHOLOGY; PHARMACOLOGY; PLURIPOTENT STEM CELL; PROGERIA; PROTEIN PRENYLATION; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

BINDING SITES; CELL DIFFERENTIATION; FARNESYLTRANSTRANSFERASE; GERANYLTRANSTRANSFERASE; HUMANS; LAMIN TYPE A; MOLECULAR DOCKING SIMULATION; OSTEOGENESIS; PLURIPOTENT STEM CELLS; PROGERIA; PROTEIN PRENYLATION; PROTEIN STRUCTURE, TERTIARY; PYRIMIDINES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84986275726     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.374     Document Type: Article

References (57)

1. Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB et al. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 2008; 358: 592-604.
2. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I et al. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003; 300: 2055.
3. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003; 423: 293-298.
4. Navarro CL, De Sandre-Giovannoli A, Bernard R, Boccaccio I, Boyer A, Genevieve D et al. Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy. Hum Mol Genet 2004; 13: 2493-2503.
5. Varela I, Pereira S, Ugalde AP, Navarro CL, Suarez MF, Cau P et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med 2008; 14: 767-772.
6. Yang SH, Chang SY, Andres DA, Spielmann HP, Young SG, Fong LG. Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria. J Lipid Res 2010; 51: 400-405.
7. Yang SH, Bergo MO, Toth JI, Qiao X, Hu Y, Sandoval S et al. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci USA 2005; 102: 10291-10296.
8. Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN et al. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2005; 102: 12879-12884.
9. Glynn MW, Glover TW. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet 2005; 14: 2959-2969.
10. Mallampalli MP, Huyer G, Bendale P, Gelb MH, Michaelis S. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2005; 102: 14416-14421.
11. Fong LG, Frost D, Meta M, Qiao X, Yang SH, Coffinier C et al. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 2006; 311: 1621-1623.
12. Yang SH, Meta M, Qiao X, Frost D, Bauch J, Coffinier C et al. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest 2006; 116: 2115-2121.
13. Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2012; 109: 16666-16671.
14. Gordon LB, Massaro J, D'Agostino RB Sr., Campbell SE, Brazier J, Brown WT et al. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation 2014; 130: 27-34.
15. Desbordes SC, Studer L. Adapting human pluripotent stem cells to high-throughput and high-content screening. Nat Protoc 2013; 8: 111-130.
16. Lee G, Ramirez CN, Kim H, Zeltner N, Liu B, Radu C et al. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol 2012; 30: 1244-1248.
17. Zhang J, Lian Q, Zhu G, Zhou F, Sui L, Tan C et al. A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 2011; 8: 31-45.
18. Liu GH, Barkho BZ, Ruiz S, Diep D, Qu J, Yang SL et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 2011; 472: 221-225.
19. Nissan X, Blondel S, Navarro C, Maury Y, Denis C, Girard M et al. Unique preservation of neural cells in Hutchinson-Gilford progeria syndrome is due to the expression of the neuralspecific miR-9 microRNA. Cell Rep 2012; 2: 1-9.
20. Blondel S, Jaskowiak AL, Egesipe AL, Le Corf A, Navarro C, Cordette V et al. Induced pluripotent stem cells reveal functional differences between drugs currently investigated in patients with hutchinson-gilford progeria syndrome. Stem Cells Transl Med 2014; 3: 510-519.
21. Soria-Valles C, Osorio FG, Gutierrez-Fernandez A, De Los Angeles A, Bueno C, Menendez P et al. NF-kappaB activation impairs somatic cell reprogramming in ageing. Nat Cell Biol 2015; 17: 1004-1013.
22. Scaffidi P, Misteli T. Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing. Nat Cell Biol 2008; 10: 452-459.
23. Cau P, Navarro C, Harhouri K, Roll P, Sigaudy S, Kaspi E et al. Nuclear matrix, nuclear envelope and premature aging syndromes in a translational research perspective. Semin Cell Dev Biol 2014; pii: S1084-9521(14)00058-5.
24. Villa-Bellosta R, Rivera-Torres J, Osorio FG, Acin-Perez R, Enriquez JA, Lopez-Otin C et al. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of hutchinson-gilford progeria syndrome that is ameliorated on pyrophosphate treatment. Circulation 2013; 127: 2442-2451.
25. Jasinski P, Welsh B, Galvez J, Land D, Zwolak P, Ghandi L et al. A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines. Invest New Drugs 2008; 26: 223-232.
26. Nallan L, Bauer KD, Bendale P, Rivas K, Yokoyama K, Horney CP et al. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem 2005; 48: 3704-3713.
27. Gupta MK, Prabhakar YS. QSAR study on tetrahydroquinoline analogues as plasmodium protein farnesyltransferase inhibitors: a comparison of rationales of malarial and mammalian enzyme inhibitory activities for selectivity. Eur J Med Chem 2008; 43: 2751-2767.
28. Eastman RT, Buckner FS, Yokoyama K, Gelb MH, Van Voorhis WC Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J Lipid Res 2006; 47: 233-240.
29. Van Voorhis WC, Rivas KL, Bendale P, Nallan L, Horney C, Barrett LK et al. Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother 2007; 51: 3659-3671.
30. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430.
31. Mathieu S, Gradl SN, Ren L, Wen Z, Aliagas I, Gunzner-Toste J et al. Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties. J Med Chem 2012; 55: 2869-2881.
32. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010; 115: 5232-5240.
33. Ryu JW, Han SY, Yun JI, Choi SU, Jung H, Ha JD et al. Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors. Bioorg Med Chem Lett 2011; 21: 7185-7188.
34. Xu G, Abad MC, Connolly PJ, Neeper MP, Struble GT, Springer BA et al. 4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors. Bioorg Med Chem Lett 2008; 18: 4615-4619.
35. Verstovsek S, Golemovic M, Kantarjian H, Manshouri T, Estrov Z, Manley P et al. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 2005; 104: 1230-1236.
36. Ethiraj KR, Aranjani JM, Khan FR. Synthesis of methoxy-substituted chalcones and in vitro evaluation of their anticancer potential. Chem Biol Drug Des 2013; 82: 732-742.
37. Leung CY, Park J, De Schutter JW, Sebag M, Berghuis AM, Tsantrizos YS. Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition. J Med Chem 2013; 56: 7939-7950.
38. Kamiya Y, Sakurai A, Tamura S, Takahashi N. Structure of rhodotorucine A, a novel lipopeptide, inducing mating tube formation in Rhodosporidium toruloides. Biochem Biophys Res Commun 1978; 83: 1077-1083.
39. Lane KT, Beese LS. Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. J Lipid Res 2006; 47: 681-699.
40. Bos JL ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
41. Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nat Rev Cancer 2011; 11: 775-791.
42. William AD, Lee AC, Goh KC, Blanchard S, Poulsen A, Teo EL et al. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo [19.3.1.1(2,6).1(8,12)]heptaco sa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/ TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer. J Med Chem 2012; 55: 169-196.
43. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438.
44. Chevallier P, Hunault-Berger M, Larosa F, Dauriac C, Garand R, Harousseau JL. A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial. Leuk Res 2009; 33: 1124-1126.
45. Burr D, Russell G. Foreword: bisphosphonates. Bone 2011; 49: 1.
46. Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002; 61: 1255-1262.
47. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992; 70: 401-410.
48. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992; 70: 389-399.
49. Bifulco M, D'Alessandro A, Paladino S, Malfitano AM, Notarnicola M, Caruso MG et al. N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A. FEBS J 2013; 280: 6223-6232.
50. Desbordes SC, Placantonakis DG, Ciro A, Socci ND, Lee G, Djaballah H et al. High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells. Cell Stem Cell 2008; 2: 602-612.
51. Andrews PD, Becroft M, Aspegren A, Gilmour J, James MJ, McRae S et al. High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules. Biochem J 2010; 432: 21-33.
52. Zhu S, Wurdak H, Wang J, Lyssiotis CA, Peters EC, Cho CY et al. A small molecule primes embryonic stem cells for differentiation. Cell Stem Cell 2009; 4: 416-426.
53. Shan J, Schwartz RE, Ross NT, Logan DJ, Thomas D, Duncan SA et al. Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat Chem Biol 2013; 9: 514-520.
54. Carlson C, Koonce C, Aoyama N, Einhorn S, Fiene S, Thompson A et al. Phenotypic screening with human iPS cell-derived cardiomyocytes: HTS-compatible assays for interrogating cardiac hypertrophy. J Biomol Screen 2013; 18: 1203-1211.
55. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
56. Krisans SK, Ericsson J, Edwards PA, Keller GA. Farnesyl-diphosphate synthase is localized in peroxisomes. J Biol Chem 1994; 269: 14165-14169.
57. Gupta SD, Mehan RS, Tansey TR, Chen HT, Goping G, Goldberg I et al. Differential binding of proteins to peroxisomes in rat hepatoma cells: unique association of enzymes involved in isoprenoid metabolism. J Lipid Res 1999; 40: 1572-1584.